A clonal human cell line that produces an antibody (IgG) against a human cytomegalovirus (HCMV) virion polypeptide of 65 kilo daltons (kDa) was established by transforming lymphocytes from a bone marrow transplant recipient with Epstein-Barr virus (EBV). Immunofluorescent staining with this antibody was positive in cells infected with two laboratory strains and several clinical isolates of HCMV, while it was negative in cells infected with herpes simplex viruses type 1 and 2, varicella-zoster virus, or EBV. Kinetic studies of the formation of the 65kDa polypeptide in infected cells showed its appearance in the cell nuclei early. In infection (12-24 hr after infection) and its later accumulation in the cytoplasm. These results suggest possible use of this monoclonal antibody for identification of HCMV infection.
Introduction
HCMV, a widely disseminated herpes virus, is a cause of life-threatening infection in immunosupressed hosts1). In our study, more than 80% of bone marrow transplant recipients showed seroconversion to HCMV antigens and increase of and-HCMV antibody-producing cells). There have been a number of reports suggesting that HCMV-induced immunoglobulins prevent severe interstitial pneumonitis due to HCMV in these recipients3). For this reason, many atempts have been made to produce human monoclonal antibodies to HCMV, but to date these attempts have met with only limited success4). In view of possible advantages of human monoclonal antibodies over murine ones5) for future use in immunological therapy and for acquisition of a wider range of antibodies against HCMV, we attempted to produce HCMV-specific human monoclonal antibodies. In this study, we have established a stable human cell line that produces an antibody of IgG class reactive with a HCMV-specific polypeptide of 65kDa, which is the most abundant component of HCMV virions and has been implicated in the induction of neutralizing antibodies6).
Materials and Methods

Cells and viruses
Two laboratory strains of HCMV, Towne and Tanaka7), and three clinical isolates from a congenitally infected newborn and bone marrow transplant recipients were used. They were propagated in human embryonic lung (HEL) cells grown in Eagle's minimum essential medium containing 10% fetal calf serum (FCS)8). Herpes simplex virus type 1 (HSV-1) strain F and type 2 (HSV-2) strain HG 52 obtained from S. Nii at Okayama University and varicella-zoster virus (VZV) strain Oka were propagated by infecting HEL cells at a multiplicity of infection of 0. Peripheral lymphocytes from three bone marrow transplant recipients and three healthy persons were infected wiyth EBV, and plated in the wells of culture plates. After three weeks, colonies of transformed cells were seen in nearly all the wells. Culture fluid of individual wells was assayed for HCMV-specific antibodies by ELISA with late antigens as target. Antibody (IgG)-positive wells were 21-90% for cell samples from bone marrow transplant recipients, whereas they were less than 7% for cell samples from healthy persons (Table 1) . Ten wells that showed O.D.>1.5 in ELISA were selected and cells contained were examined for their antibody-producing ability for several weeks. These were all derived from bone marrow transplant recipients. Cells obtained from 7 out of 10 wells turned out to be non-producers after 4 weeks. Cells from three wells continuously produced HCMV-specific antibodies for over 4 weeks without any reduction in titers. These cells were then coned by limiting dilution and three cell lines (WT-3, WT-5, WT-6) were established. These three cell lines produced 1-2 ,ug/m1 human IgG with K light chains. These antibodies are called mAb WT-3, WT-5, and WT-6. In this study, mAb WT-5 was characterized further. Table 1 Appearance of and-HCMV antibody-producing cells The viral antigen recognized by monoclonal antibodies The target antigen of mAb WT-5 was determined by immunoblotting analysis in which three types of HCMV antigens, i.e. late antigens, virion capsids, and enveloped virions, were used. As seen in Fig. 1A , mAb WT-5 recognized a 65kDa polypeptide commonly present in these three types of antigen preparation. mAb WT-3 and WT-6 similary recognized the 65kDa polypeptide (not shown). Better separation of Specific recognition of HCMV by mAb WT-5 mAb WT-5 wa able to immunofluorescent stain HEL cells infected with two laboratory strains of HCMV, Towne and Tanaka, and three clinical isolates of HCMV; no essential differences were observed in the fluorescent pattern among these strains (Fig. 2) . In contrast, no fluorescence was observed in cells infected with HSV-1, HSV-2, VZV or EBV. Immunoblotting showed that all the 65kDa polypetides produced by these five strains of HCMV share the epitope that can be recognized by mAb WT-5. The results obtained with strains Towne and Tanaka and one clinical isolate (Y) are shown in Fig. 3 . Time course of the 65kDa polypetide formation Immunofluorescent staining of infected cells with mAb WT-5 showed that the 65kDa polypeptide became detectable in the nuclei between 12 and 24 hr after infection and then accumulated predominantly in the cytoplasm between 72 and 96 hr after infection, suggesting its transport from the nuclei to the cytoplasm at late stages of infection (Fig. 4) . This is consistent with the previous observation that virions, moninfectious enveloped particles and dense bodies, all of which contain substantial amounts of the 65kDa matrix proteins, are accumlated in the cytoplasm at late stages of HCMV infectionm). Quantitativ analysis by immunoblotting and ELISA showed that the 65kDa polypeptide was first detected at 12 hr after infection, and it increased with time and reached over 100 times as much amount at 72 hr as that at 12 hr ( Fig. 5 and 6 ).
Discussion
Using the EBV-transformation technique for the production of human monoclonal antibodies9), we have established human cell lines producing the antibodies against the 65kDa virion protein of HCMV. Three cell lines thus obtained have been cultured for more than 12 months with constant production of the antibody. Of these, the chracteristics of mAb WT-5 was determined here. The use of peripheral lymphocytes from bone marrow transplant recipients appeared to be suitable for these purposes. Presumably this is due to the fact that HCMV is reactivated frequently in these immunosuppressed patients and immune responses to HCMV are potentially stimulated in them1)2).
More than 50 species of proteins specified by the HCMV genome are synthesized in infected cells and about 30 of them are associated with virions12). Historically, one particular species of virion protein was predominantly detected by immunoprecipitation in which virion components were incubated with human sera of either acute or convalescent infection with HCMV15). This virion component with an apparent molecular weight 65-69k was found to make up about 70% of the virion and named matrix protein by Gibson and Irmiere et al.12)13) This protein was later found to be composed of two species of polypeptides which were separable by PAGE, and they were accordingly named the lower and upper matrix proteins13). The 65kDa polypeptide recognized by mAb WT-5 in this study apparently corresponds to the lower matrix protein (Fig. 1A and 1B) .
mAb WT-5 appeared to be able to distinguish HCMV from other herpes viruses. So far the most sensitive method for laboratory diagnosis of active HCMV infection is the virus isolation in tissue cultures16), and at least 7 days are required for initial observation of the HCMV-induced cytopathic effect after inoculation of clinical specimens onto susceptible cells17). The present study shows that the immunofluorescent staining with mAb WT-5 can identify HCMV in cell cultures within 48 hr after inoculation (Fig. 2) , and both ELISA and immunoblotting analysis can detect the HCMV-specific antigen between 12 and 24 hr after infection ( Fig. 5 and 6 ), suggesting potential usefulness of mAb WT-5 in clinical applications.
Our preliminary tests for neutralization of HCMV infectivity with mAb WT-5 has been negative (unpublished observation). However, there is evidence that the lower matrix protein elicits both humoral18) and cell-mediated immune response in man19). In view of this, possible use of mAb WT-5 for prophylaxis and treatment of severe HCMV infection does deserve consideration.
